Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH

Mona A Hegazy,1 Sherif M Mogawer,1 Alshaimaa Rezk L R Alnaggar,1 Olfat A Ghoniem,2 Rasha M Abdel Samie1 1Internal Medicine Department, Kasr Alainy Hospital, Faculty of Medicine, Cairo University, Cairo, Egypt; 2Internal Medicine, Ministry of Health, Cairo, EgyptCorrespondence: Mona A Hegazy Tel +201...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hegazy MA, Mogawer SM, Alnaggar ARLR, Ghoniem OA, Abdel Samie RM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	non-alcoholic steatohepatitis inflammation microbiota cd163 lps. Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/53ceea8353844bc68dbcb727c3ef0c6f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:53ceea8353844bc68dbcb727c3ef0c6f
record_format	dspace
spelling	oai:doaj.org-article:53ceea8353844bc68dbcb727c3ef0c6f2021-12-02T11:11:45ZSerum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH1178-7007https://doaj.org/article/53ceea8353844bc68dbcb727c3ef0c6f2020-10-01T00:00:00Zhttps://www.dovepress.com/serum-lps-and-cd163-biomarkers-confirming-the-role-of-gut-dysbiosis-in-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Mona A Hegazy,1 Sherif M Mogawer,1 Alshaimaa Rezk L R Alnaggar,1 Olfat A Ghoniem,2 Rasha M Abdel Samie1 1Internal Medicine Department, Kasr Alainy Hospital, Faculty of Medicine, Cairo University, Cairo, Egypt; 2Internal Medicine, Ministry of Health, Cairo, EgyptCorrespondence: Mona A Hegazy Tel +201001421551Email monahegazy@cu.edu.egBackground: Gut-microbiota alterations and bacterial translocation might attribute to hepatic inflammation. Lipopolysaccharide stimulates toll-like receptor 4 leading to the activation of Kupffer cells which express the surface receptor, CD 163.Objective: To assess the levels of CD 163 and LPS in overweight and obese patients with different degrees of NAFLD as confirmed by liver biopsy (NAS score).Methods: This is an observational case–control study. Sixty overweight and obese patients with NAFLD and 40 healthy controls were enrolled in the study. Liver biopsy was obtained from all participants with NAFLD. LPS and CD 163 levels were assessed using ELISA.Results: The mean LPS and CD163 levels were significantly higher in patients with NAFLD when compared with healthy controls (p-value < 0.001, p-value < 0.001, respectively). LPS and CD163 levels were the lowest in Non-NASH (13.17 ± 3.34, 5.61 ± 2.35 ng/mL, respectively) and the highest in NASH (58.61 3± 3.81, 18.11 ± 6.84, respectively) (p-value < 0.001, p-value < 0.001, respectively). Statistically significant correlation was found between the levels of LPS and CD163 and NAS score (p-value < 0.001, p-value < 0.001, respectively), steatosis grade (p-value < 0.001, p-value < 0.001, respectively), degree of inflammation (p-value 0.017, p-value < 0.001, respectively) and ballooning (r= 0.663, p-value < 0.001, r= 0.558, p-value < 0.001, respectively). In ROC analysis, both sCD163 and LPS had high sensitivity and specificity in diagnosing NAFLD. CD163 and LPS had the high sensitivity and accuracy in discriminating NASH from Non-NASH (p-value < 0.0001 in both). Moreover, the mean serum levels of LPS and sCD163 correlated positively and significantly with the BMI (r=0.329, p value< 0.01; r=0.477. p value < 0.001, respectively).Conclusion: sCD163 and LPS can be used as non-invasive tools for diagnosis and grading of NAFLD severity in overweight and obese patients, thus confirming the role of dysbiosis in fat deposition and inflammation and suggesting the potential benefits of gut-microbiota-targeted therapies in restoring the gut homeostasis.Keywords: non-alcoholic steatohepatitis, inflammation, microbiota, CD163, LPSHegazy MAMogawer SMAlnaggar ARLRGhoniem OAAbdel Samie RMDove Medical Pressarticlenon-alcoholic steatohepatitisinflammationmicrobiotacd163lps.Specialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 3861-3872 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	non-alcoholic steatohepatitis inflammation microbiota cd163 lps. Specialties of internal medicine RC581-951
spellingShingle	non-alcoholic steatohepatitis inflammation microbiota cd163 lps. Specialties of internal medicine RC581-951 Hegazy MA Mogawer SM Alnaggar ARLR Ghoniem OA Abdel Samie RM Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH
description	Mona A Hegazy,1 Sherif M Mogawer,1 Alshaimaa Rezk L R Alnaggar,1 Olfat A Ghoniem,2 Rasha M Abdel Samie1 1Internal Medicine Department, Kasr Alainy Hospital, Faculty of Medicine, Cairo University, Cairo, Egypt; 2Internal Medicine, Ministry of Health, Cairo, EgyptCorrespondence: Mona A Hegazy Tel +201001421551Email monahegazy@cu.edu.egBackground: Gut-microbiota alterations and bacterial translocation might attribute to hepatic inflammation. Lipopolysaccharide stimulates toll-like receptor 4 leading to the activation of Kupffer cells which express the surface receptor, CD 163.Objective: To assess the levels of CD 163 and LPS in overweight and obese patients with different degrees of NAFLD as confirmed by liver biopsy (NAS score).Methods: This is an observational case–control study. Sixty overweight and obese patients with NAFLD and 40 healthy controls were enrolled in the study. Liver biopsy was obtained from all participants with NAFLD. LPS and CD 163 levels were assessed using ELISA.Results: The mean LPS and CD163 levels were significantly higher in patients with NAFLD when compared with healthy controls (p-value < 0.001, p-value < 0.001, respectively). LPS and CD163 levels were the lowest in Non-NASH (13.17 ± 3.34, 5.61 ± 2.35 ng/mL, respectively) and the highest in NASH (58.61 3± 3.81, 18.11 ± 6.84, respectively) (p-value < 0.001, p-value < 0.001, respectively). Statistically significant correlation was found between the levels of LPS and CD163 and NAS score (p-value < 0.001, p-value < 0.001, respectively), steatosis grade (p-value < 0.001, p-value < 0.001, respectively), degree of inflammation (p-value 0.017, p-value < 0.001, respectively) and ballooning (r= 0.663, p-value < 0.001, r= 0.558, p-value < 0.001, respectively). In ROC analysis, both sCD163 and LPS had high sensitivity and specificity in diagnosing NAFLD. CD163 and LPS had the high sensitivity and accuracy in discriminating NASH from Non-NASH (p-value < 0.0001 in both). Moreover, the mean serum levels of LPS and sCD163 correlated positively and significantly with the BMI (r=0.329, p value< 0.01; r=0.477. p value < 0.001, respectively).Conclusion: sCD163 and LPS can be used as non-invasive tools for diagnosis and grading of NAFLD severity in overweight and obese patients, thus confirming the role of dysbiosis in fat deposition and inflammation and suggesting the potential benefits of gut-microbiota-targeted therapies in restoring the gut homeostasis.Keywords: non-alcoholic steatohepatitis, inflammation, microbiota, CD163, LPS
format	article
author	Hegazy MA Mogawer SM Alnaggar ARLR Ghoniem OA Abdel Samie RM
author_facet	Hegazy MA Mogawer SM Alnaggar ARLR Ghoniem OA Abdel Samie RM
author_sort	Hegazy MA
title	Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH
title_short	Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH
title_full	Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH
title_fullStr	Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH
title_full_unstemmed	Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH
title_sort	serum lps and cd163 biomarkers confirming the role of gut dysbiosis in overweight patients with nash
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/53ceea8353844bc68dbcb727c3ef0c6f
work_keys_str_mv	AT hegazyma serumlpsandcd163biomarkersconfirmingtheroleofgutdysbiosisinoverweightpatientswithnash AT mogawersm serumlpsandcd163biomarkersconfirmingtheroleofgutdysbiosisinoverweightpatientswithnash AT alnaggararlr serumlpsandcd163biomarkersconfirmingtheroleofgutdysbiosisinoverweightpatientswithnash AT ghoniemoa serumlpsandcd163biomarkersconfirmingtheroleofgutdysbiosisinoverweightpatientswithnash AT abdelsamierm serumlpsandcd163biomarkersconfirmingtheroleofgutdysbiosisinoverweightpatientswithnash
_version_	1718396163044933632

Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH

Ejemplares similares